Alverin Plus Solution for Injection for Cattle

Main information

  • Trade name:
  • Alverin Plus Solution for Injection for Cattle
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Alverin Plus Solution for Injection for Cattle
    Italy
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ivermectin, combinations
  • Therapeutic area:
  • Cattle

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0399/001
  • Authorization date:
  • 22-06-2011
  • EU code:
  • UK/V/0399/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:November2011

AN:01750/2010

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

AlverinPlus10/100mg/mlSolutionforInjectionforCattle(UKandPL)

LevatumSuper10/100mg/mlSolutionforInjectionforCattle(AT,BE,CZ,EE,LV,

LU,LT,NL,PT,SK)

LevatumPlus10/100mg/mlSolutionforInjectionforCattle(ES,IT)

LevatumFluke10/100mg/mlSolutionforInjectionforCattle(DE)

LevatumD10/100mg/mlSolutionforInjectionforCattle(FR)

Levatumvet10/100mg/mlSolutionforInjectionforCattle(FI)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

1mlofsolutioncontains:

Activesubstances:

Ivermectin10mg

Clorsulon100mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection

Aclearcolourlesstopaleyellowcolouredsterilenon-aqueoussolution

4. CLINICALPARTICULARS

4.1 Targetspecies

Cattle

4.2 Indicationsforuse,specifyingthetargetspecies

Theproductisindicatedforthetreatmentofmixedinfestationofadultliverflukeandgastro-

intestinalroundworms,lungworms,eyeworms,and/ormitesandliceofbeefandnon-lactating

dairycattle.

Gastrointestinalroundworms(adultandfourth-stagelarvae):

Ostertagiaostertagi(includinginhibitedlarvalstages)

O.lyrata

Haemonchusplacei

Trichostrongylusaxei

T.colubriformis

Cooperiaoncophora

C.punctata

C.pectinata

Bunostomumphlebotomum

Revised:November2011

AN:01750/2010

Oesophagostamumradiatum

Strongyloidespapillosus(adult)

Nematodirusspathiger(adult)

Nematodirushelvetianus(adult)

Trichurisspp(adult)

Lungworms(adultandfourth-stagelarvae)

Dictyocaulusviviparus

Liverfluke(adult):

Fasciolahepatica

Eyeworms(adult):

Thelaziaspp

Warbles(parasiticstages):

Hypodermabovis

H.lineatum

Mangemites:

Psoroptesbovis

Sarcoptesscabieivar.bovis

Suckinglice:

Linognathusvituli

Haematopinuseurysternus

Solenopotescapillatus.

Theproductmayalsobeusedasanaidinthetreatmentofbitinglice(Damaliniabovis)and

themangemiteChorioptesbovis,butcompleteeliminationmaynotoccur.

Persistentactivity

Theproductgivenattherecommendeddosageof1ml/50kgbodyweightcontrolsre-infection

withHaemonchusplacei,Cooperiaspp.andTrichostrongylusaxeiacquiredupto14days

aftertreatment,OstertagiaostertagiandOesophagostomumradiatumacquiredupto21

daysaftertreatmentandDictyocaulusviviparusacquiredupto28daysaftertreatment.

4.3 Contraindications

Donotuseintramuscularlyorintravenously.

Theproductisalowvolumeproductauthorisedforuseincattle.Donotuseinotherspecies

assevereadversereactions,includingfatalitiesindogs,mayoccur(especiallyCollies,Old

EnglishSheepdogsandrelatedbreedsorcrosses)Donotuseinanimalswithknown

hypersensitivitytotheactivesubstancesortoanyoftheexcipients.

4.4Specialwarningsforeachtargetspecies

Careshouldbetakentoavoidthefollowingpracticesbecausetheyincreasetheriskof

developmentofresistanceandcouldultimatelyresultinineffectivetherapy:

Toofrequentandrepeateduseofanthelminticsfromthesameclass,overanextended

periodoftime.

Underdosing,whichmaybeduetounderestimationofbodyweight,misadministration

oftheproduct,orlackofcalibrationofthedosingdevice(ifany).

Revised:November2011

AN:01750/2010

Suspectedclinicalcasesofresistancetoanthelminticsshouldbefurtherinvestigatedusing

appropriatetests(e.g.FaecalEggCountReductionTest).Wheretheresultsofthetest(s)

stronglysuggestresistancetoaparticularanthelmintic,ananthelminticbelongingtoanother

pharmacologicalclassandhavingadifferentmodeofactionshouldbeused.

4.5 Specialprecautionsforuse

i) Specialprecautionsforuseinanimals

Thisproductdoesnotcontainanyantimicrobialpreservative.Swabseptumbeforeremoving

eachdose.

ii) Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Donotsmoke,eatordrinkwhilsthandlingtheproduct.

Washhandsafteruse.Directcontactwiththeskinshouldbeavoided.Takecaretoavoid

self-injection:theproductmaycauselocalirritationand/orpainattheinjectionsite.Incaseof

accidentalselfinjection,seekmedicaladviceandshowthelabeltothedoctor.

iii) Otherprecautions

Theproductisverytoxictoaquaticorganismsanddunginsects.Treatedcattleshouldnot

havedirectaccesstoponds,streamsorditchesfor14daysaftertreatment.Longtermeffects

ondunginsectscausedbycontinuousorrepeatedusecannotbeexcluded.Therefore

repeatedtreatmentsonapasturewithinaseasonshouldonlybegivenontheadviceofa

veterinarian.

4.6Adversereactions(frequencyandseriousness)

Transitorydiscomforthasbeenobservedinsomecattlefollowingsubcutaneous

administration.Alowincidenceofsofttissueswellingattheinjectionsitehasbeenobserved.

Thesereactionsdisappearedwithouttreatment.

4.7Useduringpregnancy,lactationorlay

Canbeusedinpregnancyandlactation.

Canbeusedinbreedinganimals.

Seesection4.11.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Dosageanddurationoftreatment

Asingledoseof1mlper50kgbodyweight,i.e.200µgivermectinand2mgclorsulonperkg

bodyweight.

Methodofadministration

Theproductshouldbeadministeredonlybysubcutaneousinjectionunderthelooseskinin

frontoforbehindtheshoulder.

Revised:November2011

AN:01750/2010

Dividedosesgreaterthan10mlbetweentwoinjectionsites.Asterile17gauge½inch(15-

20mm)needleisrecommended.Replacewithafreshsterileneedleafterevery10-12

animalsorsooneriftheneedlebecomessoiled.

Differentinjectionsitesshouldbeusedforotherparenteralproductsadministered

concurrently.Whenusingthe500mlpacksizeuseonlyautomaticsyringeequipment.Forthe

50mlpacksize,useofamultidosesyringeisrecommended.

Thetimingoftreatmentshouldbebasedonepidemiologicalfactorsandshouldbe

customisedforeachindividualfarm.Adosingprogramshouldbeestablishedbyasuitably

qualifiedperson.Toensureacorrectdosage,bodyweightshouldbedeterminedas

accuratelyaspossible;accuracyofthedosingdeviceshouldbechecked.

Ifanimalsaretobetreatedcollectivelyratherthanindividually,toavoidunder-orover-dosing,

theyshouldbegroupedaccordingtotheirbodyweightanddosedaccordingly.

Whenthetemperatureoftheproductisbelow5ºC,difficultyinadministrationmaybe

encounteredduetoincreasedviscosity.Warmingtheproductandinjectionequipmentto

about15ºCwillgreatlyincreasetheeasewithwhichtheproductcanbeinjected.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Adoseof25mlproductper50kgbodyweight(25timestherecommendeddoselevel)may

resultinaninjectionsitelesion,includingtissuenecrosis,oedema,fibrosisandinflammation.

Nootherdrug-relatedreactionshavebeenobserved.

4.11Withdrawalperiod(s)

Meatandoffal: 66days

Milk: Donotuseincattleproducingmilkforhumanconsumption.

Donotuseinnon-lactatingdairycowsincludingpregnantheifers

within60daysofcalving.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Endectocides,ivermectin,combinations

ATCvetcode:QP54AA51

5.1 Pharmacodynamicproperties

Ivermectinisamemberofthemacrocycliclactoneclassofendectocidesandhasaunique

modeofaction.Ithasbroadandpotentantiparasiticactivity.Itbindsselectivelyandwithhigh

affinitytoglutamate-gatedchlorideionchannelswhichoccurininvertebratenerveandmuscle

cells.Thisleadstoanincreaseinthepermeabilityofthecellmembranetochlorideionswith

hyperpolarisationofthenerveormusclecell,resultingandparalysisanddeathoftheparasite.

Compoundsofthisclassmayalsointeractwithotherligand-gatedchloridechannelssuchas

thosegatedbytheneurotransmittergamma-amino-butyricacid(GABA).

Themarginofsafetyforcompoundsofthisclassisattributabletothefactthatmammalsdo

nothaveglutamate-gatedchloridechannels,thatthemacrocycliclactoneshavealowaffinity

forothermammalianligand-gatedchloridechannelsandtheydonotreadilycrosstheblood-

brainbarrier.

Revised:November2011

AN:01750/2010

Clorsulonisasulfonamide.Clorsulonisrapidlyabsorbedinthebloodstream.Itisboundto

theerythrocytesandplasmawhichareingestedbythefluke.Clorsuloninhibitstheglycolytic

enzymesintheflukeanddeprivesitofitsmainsourceofmetabolicenergy.

5.2Pharmacokineticproperties

Aftersubcutaneousadministrationof2mgclorsulonand0.2mgivermectinperkgbodyweight,

theplasmaprofiledemonstratedtheslow,steadyabsorptionofivermectinwhichreacheda

maximumplasmaconcentrationatamediantimeof1.50days.Incontrast,clorsulon

appearedrapidlyabsorbedwithmaximumplasmaatamediantimeof0.25days.The

terminalhalflifeforthetwoactiveingredientsweredeterminedasfollows:379daysfor

ivermectinand3.58daysforclorsulon.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Glycerolformal

Propyleneglycol

Monoethanolamine(forpHadjustment)

6.2Incompatibilities

Intheabsenceofcompatibilitystudiesdonotmixwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Shelf-lifeafterfirstopeningtheimmediatepackaging:Followingwithdrawalofthefirstdose,

usetheproductwithin28days.Discardunusedmaterial.

6.4.Specialprecautionsforstorage

Protectfromlight.

Keepthecontainerintheoutercartoninordertoprotectfromlight.

6.5Natureandcompositionofimmediatepackaging

Containermaterial:Highdensitypolyethylene

Containerclosure: Siliconisedgreybromobutylrubberstopper

Containercolour: Natural

Containervolume: 50ml,250mlor500ml

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

EXTREMELYDANGEROUSTOFISHANDAQUATICLIFE.

Donotcontaminatesurfacewatersorditcheswiththeproductorusedcontainer.

Revised:November2011

AN:01750/2010

7. MARKETINGAUTHORISATIONHOLDER

ChanelleAnimalHealth,7RodneyStreet,LiverpoolL19HZUnitedKingdom

8. MARKETINGAUTHORISATIONNUMBER

Vm11990/4055

9. DATEOFFIRSTAUTHORISATION

29November2011

10. DATEOFREVISIONOFTHETEXT

November2011

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

1-9-2018

Spodoptera frugiperda partial risk assessment

Spodoptera frugiperda partial risk assessment

Published on: Fri, 31 Aug 2018 00:00:00 +0200 EFSA was asked for a partial risk assessment of Spodoptera frugiperda for the territory of the EU focussing on the main pathways for entry, factors affecting establishment, risk reduction options and pest management. As a polyphagous pest, five commodity pathways were examined in detail. Aggregating across these and other pathways, we estimate that tens of thousands to over a million individual larvae could enter the EU annually on host commodities. Instigat...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration